Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib maintenance vs placebo in newly diagnosed multiple myeloma ineligible for stem cell transplant
jRCT2080222821Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib maintenance with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222821.